Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

The debut of the proteasome inhibitor bortezomib (Btz; Velcade®) radically and immediately
improved the treatment of multiple myeloma (MM), an incurable malignancy of the plasma …

The majority of intracellular proteins undergo degradation through the ubiquitin-proteasome
pathway. The proteasome pathway has a role in regulating cell proliferation, differentiation …

Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the
clinical trials evaluating them in combination with other novel and established therapies …

Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of antibody-
secreting plasma cells in bone marrow, which represents the second most common …

The development of proteasome inhibitors (PIs) has transformed the treatment of multiple
myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the …

It is becoming clear that myeloma cell-induced disruption of the highly organized bone
marrow components (both cellular and extracellular) results in destruction of the marrow and …